Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Context.—: The N-terminal prohormone of the brain natriuretic peptide (NT-proBNP) is a major diagnostic biomarker for heart failure.
Objective.—: To compare the analytical and clinical performance of 3 NT-proBNP immunoassays: the Atellica IM NT-proBNP assay (Siemens Healthcare Diagnostics), the Alere NT-proBNP assay (Abbott Laboratories), and the Elecsys proBNP II assay (Roche Diagnostics).
Design.—: For the Atellica IM NT-proBNP assay, analytical performance, including precision, linearity, and carryover, was fully evaluated. Method comparisons among the 3 assays were performed using the Passing-Bablok regression and the κ agreement test. To evaluate the clinical performance of the assays, 160 patient samples were used from patients with (n = 81) or without (n = 79) heart failure.
Results.—: The analytical performance of the Atellica IM NT-proBNP assay was acceptable according to the manufacturer's claims. The Atellica IM NT-proBNP assay showed a positive bias compared with the Elecsys proBNP II assay. The Cohen κ values among the 3 assays were satisfactory (>0.80) and comparable. There were no significant differences in areas under the curve. However, for the diagnosis of heart failure, the Elecsys proBNP II showed a higher specificity and positive likelihood ratio than the other assays.
Conclusions.—: All 3 NT-proBNP assays showed acceptable concordance, and their clinical performance was comparable. However, the Elecsys proBNP II might be a more discriminating NT-proBNP assay to diagnose heart failure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5858/arpa.2021-0587-OA | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF.
Front Cardiovasc Med
August 2025
Department of Cardiology, Dongguan Tai-xin Hospital, Dongguan, China.
Objective: This study sought to identify key prognostic factors in patients with hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF), emphasizing the prognostic role of free triiodothyronine (FT3) levels.
Research Design And Methods: This retrospective cohort study enrolled 992 HCM-HFpEF patients from two Chinese medical centers between 2009 and 2019, excluding those with thyroid-affecting medications or disorders. Data on demographic and clinical variables, including FT3, were analyzed using univariate and multivariate Cox regression, Kaplan-Meier (KM) survival analysis, and restricted cubic spline (RCS) analysis to explore prognostic factors and FT3's nonlinear predictive value.
Ethnic differences in protein biomarkers of peripartum cardiomyopathy: a proteomic study on the EORP cohort.
ESC Heart Fail
September 2025
Cape Heart Institute, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Aims: The diagnosis of peripartum cardiomyopathy (PPCM) is often delayed due to the absence of disease-specific biomarkers. Recently, serum proteins-QSOX1, adiponectin (ADIPOQ) and ITIH3-have shown potential for improving diagnostic accuracy, especially when used with NT-proBNP. However, the influence of ethnicity on their expression remains unclear.
View Article and Find Full Text PDFMechanistic insights into Shengxian Sanren granules' effects on chronic heart failure: A synergistic study of UPLC-Q-TOF-MS/MS and network pharmacology.
Fitoterapia
August 2025
Department of Cardiovascular Medicine, Branch of National Clinical Research Center for Chinese Medicine Cardiology, The First Hospital of Hunan University of Chinese Medicine, Changsha, China. Electronic address:
Objective: This study aims to elucidate the pharmacological mechanisms and therapeutic targets of Shengxian Sanren Granules in the treatment of Chronic heart failure (CHF), with particular emphasis on the regulation of the PI3K/AKT/mTOR-mediated autophagy signaling pathway.
Methods: The major blood-absorbed components of Shengxian Sanren Granules were identified using ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS/MS). Network analysis was applied to predict potential targets and signaling pathways, revealing 37 core targets predominantly enriched in the PI3K-Akt and mTOR pathways.
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.
Lancet
August 2025
Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.
Background: Following completion of the VICTORIA trial, vericiguat was approved for the treatment of worsening heart failure with reduced ejection fraction (HFrEF) and received a class IIb recommendation in European and North American guidelines. The subsequent VICTOR trial evaluated the use of vericiguat in patients with HFrEF and no recent worsening. We aimed to assess the effect of vericiguat on clinical endpoints through pooled analyses of patient-level data from the VICTORIA and VICTOR trials.
View Article and Find Full Text PDFBiomarkers of Atrial Fibrillation-Related Pathways and Left Atrial Structure and Function in an Overweight and Obese Population.
Cureus
July 2025
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, USA.
Background Exploring longitudinal associations of blood biomarkers with left atrial (LA) structure and function can enhance our understanding of atrial fibrillation (AF) etiopathogenesis. Methods We studied 532 participants of the PREDIMED-Plus trial, a multicenter randomized trial in overweight and obese adults with metabolic syndrome. At baseline, 3 and 5 years after randomization, participants underwent transthoracic echocardiography and provided blood for serum biomarker measurements (propeptide of procollagen type I (PICP), high-sensitivity (hs) troponin T (hsTnT), hs C-reactive protein (hsCRP), 3-nitrotyrosine (3-NT), and N-terminal propeptide of B-type natriuretic peptide (NT-proBNP)).
View Article and Find Full Text PDF